Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 12/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 7/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL324460 | 1.00 | PNMT (1.00) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL27698594 | 0.98 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL29651180 | 0.98 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL325622 | 0.98 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1269277 | 0.93 | PNMT (0.87) | PNMTADRA2AADRA2BADRA2C | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL5485986 | 0.92 | PNMT (0.85) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL10004303 | 0.92 | PNMT (0.84) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1074232 | 0.90 | PNMT (0.82) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL717840 | 0.89 | PNMT (0.81) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL1947220 | 0.88 | PNMT (0.78) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111621805-B | Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation | 天津大学 | 2022-02-18 | — | — | CN | claimed |
| CN-117886824-B | 2, 3-Dihydropyrimido [4,5-d ] pyrimidine-4 (1H) -ketone derivative, preparation method and application thereof | 四川大学华西医院 | 2026-05-15 | — | — | CN | disclosed |
| CN-119707835-A | 2-Aminopyrimidine-5-carboxamide compounds and use thereof for the production of medicaments for the treatment and/or prophylaxis of cancer | 沈阳药科大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-115872985-B | 1,2,3, 4-Tetrahydroisoquinoline-thiophene derivative and preparation method thereof | 赣江中药创新中心 | 2025-01-14 | — | — | CN | disclosed |
| CN-119241559-A | Quinazoline macrocyclic compound serving as HPK1 kinase inhibitor and preparation method and application thereof | 深圳市新樾生物科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-12-26 | — | — | US | disclosed |
| CN-118619800-A | Amino dithioformate compound and preparation method thereof | 抚州三和医药化工有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-118451069-A | Heterocyclic compounds | 正大天晴药业集团股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| CN-117886824-A | 2, 3-dihydropyrimido [4,5-d ] pyrimidine-4 (1H) -ketone derivative, preparation method and application thereof | 四川大学华西医院 | 2024-04-16 | — | — | CN | disclosed |
| CN-116867787-A | Pyrazolo [3,4-d ] pyrimidin-3-one derivatives | 微境生物医药科技(上海)有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-111094253-B | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs | 里科瑞尔姆IP控股有限责任公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-113150009-B | Heterocyclic compound with activity of inhibiting programmed cell necrosis pathway and application thereof | 爱科诺生物医药(香港)有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-115872985-A | 1,2,3, 4-tetrahydroisoquinoline-thiophene derivative and preparation method thereof | 赣江中药创新中心 | 2023-03-31 | — | — | CN | disclosed |
| CN-115515579-A | Pyrrolo [2,3-b ] pyridine-3-carboxamide compositions and methods for ameliorating hearing loss | 洛克菲勒大学 | 2022-12-23 | — | — | CN | disclosed |
| EP-4085059-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | Accro Bioscience (HK) Limited (HK) | 2022-11-09 | — | — | EP | disclosed |
| WO-2022214869-A2 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2022-10-13 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022147210-A1 | ANTI-TUMOR COMPOSITIONS AND METHODS | EVRYS BIO, LLC (US) | 2022-07-07 | — | — | WO | disclosed |
| CN-111621805-B | Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation | 天津大学 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | PMS2, MSH2, RECQL | PNMT 1175/4885ADRA2A 968/4885ADRA2B 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.